Cargando…

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance

Detalles Bibliográficos
Autores principales:	Ahn, Hyein, Kwon, Hyun Jung, Park, Eunhyang, Kim, Hyojin, Chung, Jin-Haeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pathologists and the Korean Society for Cytopathology 2018
Materias:	Brief Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859235/ https://www.ncbi.nlm.nih.gov/pubmed/28372343 http://dx.doi.org/10.4132/jptm.2016.11.17

Ejemplares similares

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Metaplastic carcinoma with osteosarcomatous differentiation in the breast: Case report
por: Asare, Belinda, et al.
Publicado: (2023)

Left Atrial High-grade Sarcoma With Focal Osteosarcomatous Differentiation
por: Napuri, Jessica, et al.
Publicado: (2020)

Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component
por: Sun, Wenbin, et al.
Publicado: (2012)

Retroperitoneal dedifferentiated liposarcoma with osteosarcomatous dedifferentiation
por: Nguyen, Vinh N., et al.
Publicado: (2015)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
por: Matsuda, Asako, et al.
Publicado: (2019)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Carcinosarcoma with Choriocarcinomatous and Osteosarcomatous Differentiation in a Patient with Juvenile Polyposis Syndrome
por: Parra-Medina, Rafael, et al.
Publicado: (2015)

A challenging diagnosis of malignant mesothelioma with osteosarcomatous differentiation metastasizing to bone
por: Brown, Michael, et al.
Publicado: (2020)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
por: Rajamäki, Aino, et al.
Publicado: (2022)

Basal cell carcinosarcoma of the eyelid with osteosarcomatous transformation
por: Heathcote, John G., et al.
Publicado: (2021)

A case of hepatic leiomyosarcoma with osteosarcomatous differentiation (malignant mesenchymoma) in a dog
por: Takai, Yuichi, et al.
Publicado: (2019)

Breast Metaplastic Carcinoma With Osteosarcomatous Differentiation: A Case Report and literature Review
por: Yang, Xue, et al.
Publicado: (2022)

Case report: Osteosarcomatous differentiation in the lung metastasis of a malignant phyllodes tumor
por: Liu, Ruijing, et al.
Publicado: (2023)

High grade phyllodes tumor with osteosarcomatous differentiation: Case report and review of the literature
por: Hall, Rachel R., et al.
Publicado: (2023)

Heterotopic Pancreas in Omphalomesenteric Duct Remnant Results in Persistent Umbilical Discharge
por: Park, Eunhyang, et al.
Publicado: (2014)

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
por: Lee, Ting-Fang, et al.
Publicado: (2018)

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
por: Lee, Jeonghyo, et al.
Publicado: (2022)

Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
por: Park, Hee Sun, et al.
Publicado: (2021)

Osteosarcomatous Divergence in Dedifferentiated Liposarcoma Presenting as a Colonic Mass
por: Gordhandas, Jeenal, et al.
Publicado: (2019)

The correlation of p22(phox) and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma
por: Kobayashi, Masayuki, et al.
Publicado: (2019)

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
por: Chen, Hongjin, et al.
Publicado: (2021)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
por: Gieszer, Balazs, et al.
Publicado: (2021)

Malignant peripheral nerve sheath tumor with extensive osteosarcomatous and chondrosarcomatous differentiation: A case report
por: Meshikhes, Abdul-Wahed N., et al.
Publicado: (2016)

Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
por: Kim, Hyojin, et al.
Publicado: (2022)

Rebiopsy rate after transperineal or transrectal prostate biopsy
por: Marenco Jimenez, Jose L., et al.
Publicado: (2021)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

The characteristics and spatial distributions of initially missed and rebiopsy-detected prostate cancers
por: You, Myung-Won, et al.
Publicado: (2016)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
por: Saito, Ryoko, et al.
Publicado: (2018)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
por: Kim, Chi Hong, et al.
Publicado: (2015)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
por: Yu, Jiang-Yong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ups8t3n88avqrrq3kgvivugv1q